Informed decisions are key. Clinical rationale makes all the difference in medicine.
MS involves B-cell activity and its endothelial and neurological impacts. A treatment needs to tackle this precisely.
To clarify, the Somata Genesis protocol is not a stem cell therapy. Everything that it is gets defined only by MS.
The cerebrovascular procedure involves catheterized administration to the supratentorial region of the brain via the sigmoid sinuses. Somata Genesis developed this procedure during its MS research and remains the only organization in the world performing this protocol. This is NOT the same as an intrathecal.
Furthermore, this isn’t a vague ‘stem cell’ treatment down in Mexico.
In MS, the supratentorial region and the surrounding areas, including the corpus callosum, are primarily affected, particularly by demyelinating plaques (as noted in the sagittal MRI view). The cerebrovascular access provides the closest safe pathway to this region.
Conditions such as cerebral venous sinus thrombosis, IJV stenosis, Eagle’s syndrome, or lymphovenous obstructions inhibit the outflow of cerebrospinal fluid and deoxygenated blood, resulting in intracranial pressure symptoms (headaches, vertigo, tinnitus) in an MS patient. This lack of outflow not only prevents the timely entry of oxygenated blood to the brain, causing ischaemic changes, but also renders neuroendocrine symptoms due to excessive pituitary compression, a phenomenon also commonly noted in MS patient MRIs as empty sella syndrome.
Fresh ischaemic changes often get noted by the neurologist as juxtacortical lesions. Without addressing these flow obstructions, no regenerative approach will succeed in MS.
This is the primary reason Somata Genesis developed the cerebrovascular preconditioning protocol. To aid the regeneration of thrombosis in the cerebral venous sinuses, the research delved into endothelial tissue regeneration, followed swiftly by the incorporation of precise growth factors to induce angiogenesis in the brain.
A neural cellular mix was incorporated as a finishing touch to precisely replicate neurogenesis and neuroplasticity, which occur naturally in a young brain.
For higher EDSS subjects, a third procedure is rendered to address foraminal narrowing and radiculopathy, which commonly mimic neuropathy and limb spasticity in MS patients at EDSS >5.
MS defined this treatment, not the other way around. The MS cascade of events cannot be explained or addressed by the average Mexican Stem Cell spa. Spending thousands of dollars and receiving intrathecal injections of unknown products being referred to as ‘stem cells’ is not the same as a clinically regulated protocol being developed specifically for MS.
It all boils down to the patient’s informed decision. The most important question is: can the patient make informed decisions and understand the disease and its treatment?
The very fact that you regarded this protocol as basically the same as something offered at a Mexican spa is where the problem is. It’s not your fault, but a catastrophic failure of the medical system in helping you make informed decisions. The Spa just grabbed the opportunity.